Listen & follow The Money with Katie Show: Apple Podcasts | Spotify

Welcome back to Part Two of our series, the Economics of Weight Loss Drugs. (If you haven’t heard Part One, listen here!)

Today, we’re picking back up where we left off in our conversation with Lili Zarghami, a writer who got on (then off) a weight loss drug. Then we’ll talk with Dr. Mara Gordon, a weight-neutral physician who deals with GLP-1s. Plus, I’ll share my final thoughts and analysis on where the world of GLP-1 agonists is all headed and what it says about health, wealth, stigma, and class.

📙 PRE-ORDERS FOR RICH GIRL NATION ARE LIVE.

💰 THE 2025 MONEY WITH KATIE WEALTH PLANNER IS LIVE—GET YOURS NOW.

Our show is a production of Morning Brew and is produced by Henah Velez and Katie Gatti Tassin, with our audio engineering and sound design from Nick Torres. Devin Emery is our Chief Content Officer and additional fact checking comes from Scott Wilson.

—

Mentioned in the Episode

• Tressie McMillan Cottom: “Oprah, Ozempic, and Us” (New York Times)

• Lili Zarghami’s series on getting on (and then off) Mounjaro (Jenny Magazine)

• NPR article on Kate Manne’s book Unshrinking

• Fearing the Black Body by Sabrina Strings; audio clip in conversation with NPR

• Charles Piller for science.org

• Dr. Mara Gordon for NPR

• “The economics of thinness (Ozempic edition)” (The Economist)

• Aubrey Gordon: “On ‘tough love’ and your fat friend’s health.”